Reimbursement coding information for SINOGRAFIN (Diatrizoate Meglumine and Iodipamide Meglumine Injection). Please see important disclaimer information below.
Injectable Contrast Agent
|X-Ray Ionic Products
||2017 HCPCS Code
||HCPCS Billing Units:
|SINOGRAFIN® (Diatrizoate Meglumine and Iodipamide Meglumine Injection)
||HOCM 350-399 mg/mL iodine
||10 x 10 mL vials / box
The information provided above is general reimbursement information for SINOGRAFIN (Diatrizoate Meglumine and Iodipamide Meglumine Injection). It is not legal advice, nor is it advice about how to code, complete or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider’s responsibility to determine and submit appropriate codes, charges, modifiers and bills for the services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.
Our reimbursement experts can assist you in finding answers to coding and reimbursement questions.
Contact the Bracco Reimbursement Hotline at:
Ask coding and billing questions regarding Bracco Diagnostics products and procedures related to those products.
- Coding for products and procedures
- Medicare payment
Bracco Diagnostics Inc. is pleased to provide customers with reimbursement support for products manufactured by the company and for medical procedures related to those products based on Medicare reimbursement policies. Because private payer coverage policies and benefit plans greatly differ, the information offered in this guide may not be applicable for billing and reporting to private payers. The treating provider is responsible for determining the medical necessity for each specific patient case. Claims submitted to payers should reflect the medical decisions made by the treating provider, current applicable state and federal regulations, and the provisions of the patient benefit plan. Bracco Diagnostics Inc. adheres to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) provisions and other applicable state and federal laws concerning the disclosure of protected health information (PHI). Our Reimbursement Services department does not enter into Business Associate Agreements (BAA) with customers. Therefore your institution should not disclose PHI to Bracco reimbursement representatives during the course of receiving reimbursement support.